The total sales of the top 10 antidiabetic drugs in 2018 is US $28.5 billion. How is the performance of each market?

[market analysis of chinapharma.com] according to statistics, the total sales revenue of the top 10 antidiabetic drugs in the world in 2018 is US $28.5 billion Among them, as the main drug of diabetes mellitus, insulin products, many products are facing the threat of generic drugs, the market is suffering from internal and external problems, and the market share of several heavyweight drugs is gradually divided According to the analysis of the insiders, the author summarized the market trend of the top 10 hypoglycemic drugs The sales volume of lilalutide in the past 18 years reached US $4.468 billion (the same below) The growth rate is 14.28% Lilalutide is a kind of human glucagon like peptide-1 (GLP-1) analogue, which is used to treat diabetes On January 25, 2010, the US Food and Drug Administration (FDA) approved the listing of lilalutide in the US On April 13, 2011, it was approved by the State Food and Drug Administration for the treatment of adult type 2 diabetes On October 9, 2011, it was officially listed in China 18 year sales of insulin glargine: 42.1 growth rate: - 19.39% insulin glargine is a kind of human insulin analogue with low solubility in neutral pH solution, an antidiabetic drug In fact, insulin glargine is a kind of modified insulin, which belongs to long-term insulin It can be maintained for a long time by changing the amino acid of Insulin protein and slightly adjusting the formula In 2018, the sales volume of insulin glargine produced by Sanofi was US $4.210 billion, while in 2017, the sales volume was US $5.223 billion, with a growth rate of - 19.30% The market performance declined Sales volume of sigletin in 18 years: 36.86 growth rate: - 1% sigletin belongs to dipeptidyl peptidase-4 (DPP-4) inhibitor, which can be used alone or combined with other oral hypoglycemic drugs to treat type 2 diabetes Its advantages are good safety, low incidence of adverse reactions of hypoglycemia and weight gain The growth rate of sigletin has declined, but mosadon, with its tumor immunity shining, seems to have no time to take into account the generic threat faced by sigletin, the leading diabetes product, and there is not much dazzling product follow-up on the R & D pipeline Dula glycopeptide 18 year sales: 31.99 growth rate: 58% Lilly China announced that its weekly preparation of GLP-1 receptor agonist, doyida ® (Dula glycopeptide), was officially approved by the State Drug Administration to enter China, which is applicable to the blood glucose control of adult type 2 diabetes patients, including single drug and patients who still have poor blood glucose control after being treated with metformin and / or sulfonylurea After 26 weeks of treatment, dulaglutide reduced HbA1c by 1.73% and reached blood glucose standard by 64.8% Among Chinese patients with HbA1c ≥ 8.5%, dulaglutide reduced HbA1c by 2.3% In addition, its market growth rate is very eye-catching 18 year sales of recombinant insulin: 29.97 growth rate: 5% recombinant insulin is a human insulin analogue produced by gene recombination technology, which is produced by exchanging the 28th and 29th amino acids in insulin B chain Recombined insulin lysine is a product with high sales volume in Lilly diabetes market It has a quick effect and a shorter duration, which is more in line with the insulin secretion curve during the physiological meal In April 1996, the United States Food and Drug Administration (FDA) approved the treatment of diabetes At present, due to the impact of new hypoglycemic drugs, the growth rate of recombinant insulin is relatively weak, with a growth rate of 5% 18 year sales of aspartic insulin: 29.70 growth rate: - 2% aspartic insulin is produced by Novo Nordisk, which is an insulin analogue used to treat diabetes and is a colorless clear liquid In 2018, the sales volume of asparagus insulin was US $2.97 billion, while in 2017, the sales volume was US $3.06 billion, with an increase rate of - 2% In order to meet the growing demand of diabetes patients in China and ensure the stable and convenient supply of insulin products, Novo Nordisk (China) invested 3 billion yuan to build an insulin preparation factory in Tianjin Economic Development Zone The 18 year sales volume of sitagliptin metformin: 22.28 growth rate: 3% sitagliptin metformin tablet can directly attack the three major defects of type 2 diabetes mellitus: insulin deficiency, insulin resistance and liver sugar excess output caused by islet damage, providing an optimized treatment option for patients In addition, insulin gliptin metformin tablets also provide two convenient dosage forms of different specifications, which can be selected according to the existing treatment plan of patients, so that more patients with type 1 diabetes benefit Sales volume of insulin Di in 18 years: 17.7 growth rate: - 17% insulin Di is produced by yeast through gene recombination technology Experts say that unlike most insulin, long-acting basic insulin, similar to ditorin, can not bring significant weight gain while controlling blood sugar safely and effectively, which has been confirmed in a number of clinical studies In 2017, the sales volume of Dieter insulin was US $2.157 billion, and in 2018, the sales volume was US $1.77 billion, with a growth rate of - 17% It is also one of the products with low growth rate among the top 10 hypoglycemic drugs 18 year sales of insulin aspartame / Protamine Insulin aspartame: 15.0 growth rate: - 3% Aspartic insulin / protamine aspartic insulin is a premixed insulin Experts introduced that in order to meet the further needs, the imported Insulin mixed the short-term and medium-term preparations (R and N) in different proportions, producing the premixed insulin with the action time between them In 2017, the sales volume of insulin asparagus / protamine was US $1567 million, while in 2018, the sales volume was US $1.5 billion, with a growth rate of 3% 18 year sales volume of human insulin: 14.7 growth rate: - 7% human insulin is produced by gene recombination technology, which can regulate glucose metabolism, promote the uptake and utilization of glucose by liver, bone and fat tissue, promote the conversion of glucose into glycogen, store it in muscle and liver, and inhibit glycogenesis The author understands that since the market of recombinant insulin analogues, the growth rate of sales has greatly exceeded that of recombinant human insulin From the current global sales analysis, the products of recombinant insulin analogues have occupied 80% of the global insulin market.